Georgiou Anastasia, Gomatos Ilias P, Pararas Nikolaos B, Giotakis John, Ferekidis Eleutherios
Department of Otolaryngology, Hippocration Hospital, Athens Medical School, Athens, Greece.
Ann Otol Rhinol Laryngol. 2003 Mar;112(3):206-13. doi: 10.1177/000348940311200303.
Cellular proliferation and apoptosis are both implicated in the process of carcinogenesis. The objective of this study was to access the prognostic significance of the expression of proliferating cell nuclear antigen (PCNA) and the apoptosis-related genes (bax, bcl-2, and p53) in laryngeal carcinoma patients. Thirty consecutive patients with stage I to IV squamous cell laryngeal carcinoma were treated in our department from 1992 to 1994. We immunohistochemically studied the expression of PCNA and bax, bcl-2, and p53 genes in their tumor specimens. Five healthy men were used as the control group. The staining results were correlated with clinicopathologic data. The PCNA protein expression was correlated with a significantly worse survival in those patients who were bax-negative (0% versus 42.86%, p = .0445). Similarly, the presence of PCNA led to an unfavorable clinical outcome in those patients who were bax-negative, bcl-2-negative, and p53-negative (0% versus 50%, p = .0278). Expression of bcl-2 protein was found to be an independent prognostic factor related to an unfavorable clinical outcome (p = .0262). The expression of bcl-2 protein appears to predict survival in laryngeal carcinoma patients. Furthermore, the combined study of proliferation markers and apoptosis-related genes helped us to identify a high-risk group of patients who may benefit from a more aggressive treatment protocol.
细胞增殖和凋亡均与致癌过程有关。本研究的目的是评估增殖细胞核抗原(PCNA)以及凋亡相关基因(bax、bcl-2和p53)的表达在喉癌患者中的预后意义。1992年至1994年,我们科室连续收治了30例I至IV期鳞状细胞喉癌患者。我们对他们肿瘤标本中PCNA以及bax、bcl-2和p53基因的表达进行了免疫组织化学研究。选取5名健康男性作为对照组。将染色结果与临床病理数据相关联。在bax阴性的患者中,PCNA蛋白表达与显著较差的生存率相关(0%对42.86%,p = 0.0445)。同样,在bax阴性、bcl-2阴性和p53阴性的患者中,PCNA的存在导致了不良的临床结局(0%对50%,p = 0.0278)。发现bcl-2蛋白表达是与不良临床结局相关的独立预后因素(p = 0.0262)。bcl-2蛋白的表达似乎可以预测喉癌患者的生存情况。此外,增殖标志物和凋亡相关基因的联合研究帮助我们识别出可能从更积极治疗方案中获益的高危患者群体。